Statement: the secondary trial and the primary trial use similar outcome measures, evaluating how long patients survive after treatment.
Primary_evidence: Outcome Measurement:    Disease-free Survival After Prolonged Endocrine Treatment   To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival.   Time frame: DFS was defined as the time from two years after randomization to the earliest occurrence of loco-regional recurrence, distant recurrence, contralateral new breast cancer, second cancer or death from any cause, assessed up to a maximum of 8.5 years Results 1:    Arm/Group Title: Arm A: Anastrozol   Arm/Group Description: 1 mg per day for 2 years   Overall Number of Participants Analyzed: 1281   Median (Inter-Quartile Range)   Unit of Measure: Years  NA  [1]    (7.7 to NA) Results 2:    Arm/Group Title: Arm B: Anastrozol   Arm/Group Description: 1 mg per day for 5 years   Overall Number of Participants Analyzed: 1323   Median (Inter-Quartile Range)   Unit of Measure: Years  NA  [1]    (8.1 to NA)
Secondary_evidence: Outcome Measurement:    Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer   The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported.   Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days) Results 1:    Arm/Group Title: DS-8201a   Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle.   Overall Number of Participants Analyzed: 49   Measure Type: Count of Participants   Unit of Measure: Participants  Maximum change from baseline in QTcF: >30 ms: 3   6.1%   Maximum change from baseline in QTcF: >60 ms: 0   0.0%